In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Almirall: Adapting Primary-Care-focused R&D to a Specialist World

Executive Summary

Late-stage COPD candidate aclidinium could transform mid-sized Almirall. This is what’s exciting the dozen or more analysts that cover such long-acting muscarinic antagonists; it’s the potential $2 billion drug that “could double or treble the size of this company in a very short time,” sums up one analyst. At the same time, the newly-listed company's other challenge is to monetize the fruits of its primary-care-focused R&D in a world that's going specialist.
Advertisement

Related Content

Pharma's New Follow-On Strategy
Genzyme/Isis: Has ENHANCE Dulled Mipomersen's Prospects?
Pharma's New Follow-On Strategy
Europe's New Spec Pharma Models
Europe's New Spec Pharma Models
Finding a Way Out of Pharma's Dealmaking Dilemma
BMS Deals Diabetes Drugs, Solidifies Specialist Stance
Pfizer Trims Altana From Pipeline
Pfizer Trims Altana From Pipeline
Pierre Fabre: Time to Reap R&D Rewards In-House

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel